Novartis (NYSE:NVS)‘s stock had its “neutral” rating reaffirmed by equities researchers at JPMorgan Chase & Co. in a report issued on Thursday.
A number of other equities research analysts also recently weighed in on NVS. Zacks Investment Research downgraded shares of Novartis from a “buy” rating to a “hold” rating in a report on Thursday, September 21st. Leerink Swann upped their price target on shares of Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Barclays downgraded shares of Novartis from an “equal weight” rating to an “underweight” rating in a report on Wednesday, October 25th. Bank of America downgraded shares of Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Finally, Nord/LB reissued a “neutral” rating on shares of Novartis in a report on Wednesday, December 27th. Five investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $85.32.
Novartis (NVS) traded up $0.53 during mid-day trading on Thursday, reaching $86.94. 770,420 shares of the company traded hands, compared to its average volume of 801,800. The firm has a market capitalization of $204,411.06, a P/E ratio of 30.94, a P/E/G ratio of 2.31 and a beta of 0.73. Novartis has a 1-year low of $69.53 and a 1-year high of $87.29. The company has a quick ratio of 0.81, a current ratio of 1.08 and a debt-to-equity ratio of 0.32.
Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.25 by $0.04. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The company had revenue of $12.41 billion during the quarter, compared to the consensus estimate of $12.21 billion. During the same period in the prior year, the company earned $1.23 EPS. Novartis’s revenue was up 2.4% on a year-over-year basis. sell-side analysts expect that Novartis will post 4.79 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of the company. Hall Laurie J Trustee increased its holdings in Novartis by 0.3% in the second quarter. Hall Laurie J Trustee now owns 16,713 shares of the company’s stock worth $1,395,000 after buying an additional 50 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in Novartis by 1.8% in the second quarter. Sunbelt Securities Inc. now owns 5,013 shares of the company’s stock worth $418,000 after buying an additional 90 shares during the last quarter. Roberts Glore & Co. Inc. IL increased its holdings in Novartis by 1.3% in the second quarter. Roberts Glore & Co. Inc. IL now owns 12,705 shares of the company’s stock worth $1,060,000 after buying an additional 165 shares during the last quarter. Logan Capital Management Inc. increased its holdings in Novartis by 1.6% in the second quarter. Logan Capital Management Inc. now owns 12,861 shares of the company’s stock worth $1,073,000 after buying an additional 200 shares during the last quarter. Finally, South Texas Money Management Ltd. increased its holdings in Novartis by 4.8% in the second quarter. South Texas Money Management Ltd. now owns 5,202 shares of the company’s stock worth $434,000 after buying an additional 236 shares during the last quarter. Institutional investors own 10.85% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “JPMorgan Chase & Co. Reiterates “Neutral” Rating for Novartis (NVS)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/21/jpmorgan-chase-co-reiterates-neutral-rating-for-novartis-nvs.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.